Document is current
Any future updates will be listed below
-
Authors
Ma, Xiaoxiao
Riaz, Nadeem https://orcid.org/0000-0001-9873-5862
Samstein, Robert M. https://orcid.org/0000-0001-6860-2401
Lee, Mark
Makarov, Vladimir
Valero, Cristina https://orcid.org/0000-0003-3397-2888
Chowell, Diego
Kuo, Fengshen https://orcid.org/0000-0003-1797-2896
Hoen, Douglas
Fitzgerald, Conall W. R. https://orcid.org/0000-0003-4700-7261
Jiang, Hui
Alektiar, Jonathan
Alban, Tyler J.
Juric, Ivan
Parthasarathy, Prerana Bangalore
Zhao, Yu
Sabio, Erich Y.
Verma, Richa
Srivastava, Raghvendra M. https://orcid.org/0000-0001-6545-3957
Vuong, Lynda
Yang, Wei
Zhang, Xiao
Wang, Jingming https://orcid.org/0000-0001-7297-4873
Chu, Lawrence K. https://orcid.org/0000-0001-5879-9490
Wang, Stephen L. https://orcid.org/0000-0002-3519-5130
Kelly, Daniel W.
Pei, Xin https://orcid.org/0000-0001-9961-6152
Chen, Jiapeng
Yaeger, Rona
Zamarin, Dmitriy https://orcid.org/0000-0002-0094-0161
Zehir, Ahmet https://orcid.org/0000-0001-5406-4104
Gönen, Mithat
Morris, Luc G. T. https://orcid.org/0000-0002-4417-2280
Chan, Timothy A. https://orcid.org/0000-0002-9265-0283
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA205426)
STARR Cancer Consortium
- License Information
-
More Information
Article History
Received: 23 April 2021
Accepted: 26 May 2022
First Online: 11 July 2022
Competing interests
: T.A.C. is a cofounder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. T.A.C. has served as an advisor for Bristol-Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca and An2H. T.A.C., L.G.T.M., R.M.S. and D.C. are inventors on intellectual property held by MSKCC on using tumor mutation burden to predict immunotherapy response, with pending patent, which has been licensed to PGDx. C.V. acknowledges research grant funding from Fundación Alfonso Martín Escudero. D.Z. received consulting fees from Agenus, Hookipa Biotech, Targovax, AstraZeneca, Synthekine, Mana Therapeutics, Xencor, Crown Biosciences and Memgen. D.Z. receives grant/research support from AstraZeneca, Roche and Plexxikon. D.Z. holds stock options for Immunos Therapeutics, Calidi Biotherapeutics, Mana Therapeutics and Accurius. D.Z. has a patent related to use of Newcastle Disease Virus for cancer therapy with royalties paid from Merck. R.Y. has served as an advisor for Natera, Array BioPharma/Pfizer and Mirati Therapeutics and has received research support to her institution from Array BioPharma/Pfizer, Boehringer Ingelheim and Mirati Therapeutics. The remaining authors declare no competing interests.
